News about Global Pharma

Trevi Therapeutics Welcomes James V. Cassella as Chief Development Officer

Jim will play an integral role in progressing Haduvio by utilizing his broad drug development experience and his proven hands-on leadership of scientific and regulatory teams through drug approvals.

Global Pharma | 01/10/2024 | By Aishwarya |  590

Piramal Pharma to Invest USD 80 Million for Expansion of Sterile Injectables Facility in Kentucky

The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new laboratory, and state-of-the-art machinery to scale clients’ products effectively.

Global Pharma | 01/10/2024 | By Aishwarya |  1008

Lupin Signs Distribution Deal with Celnova for Orphan Drug NaMuscla

Celnova will commercialize NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.

Global Pharma | 30/09/2024 | By Aishwarya |  734

AbbVie Submits BLA to FDA for Teliso-V in Previously Treated Non-Small Cell Lung Cancer

AbbVie has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V).

Global Pharma | 30/09/2024 | By Aishwarya |  572

Sun Pharma Presents New Clinical Efficacy and Safety Data in Dermatology at EADV Congress

The company will also share results in two additional posters for deuruxolitinib, which showed clinically meaningful improvement in anxiety and depression among patients taking deuruxolitinib to treat their severe AA (P2022) as well as dose optimization for deuruxolitinib at 8 mg (P2081).

Global Pharma | 27/09/2024 | By Aishwarya |  1010

Biocon Join Hands with Tabuk Pharma to Commercialize its GLP -1 Products in Middle East

The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage.

Global Pharma | 27/09/2024 | By Aishwarya |  1062

UCB Gets FDA Approval for BIMZELX for Treatment of Psoriatic Arthritis

BIMZELX is the first approved treatment for these three indications that is designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Global Pharma | 24/09/2024 | By Aishwarya |  1126

Antengene Receives Approval for XPOVIO for Commercialisation in Thailand

This successful approval for XPOVIO in Thailand will introduce novel therapies to the clinical management of patients with MM in Thailand, benefiting many patients and their families in the country.

Global Pharma | 24/09/2024 | By Aishwarya |  759

Agilent Announces Acquisition of BIOVECTRA

With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing.

Global Pharma | 24/09/2024 | By Aishwarya |  708

Vicebio Raises USD 100 Million in Series B Financing Round

Vicebio is developing next-generation vaccines for respiratory viruses utilising its proprietary Molecular Clamp technology, discovered at The University of Queensland.

Global Pharma | 23/09/2024 | By Aishwarya |  625